X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (303) 303
Publication (37) 37
Book Chapter (5) 5
Book / eBook (3) 3
Reference (3) 3
Web Resource (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (138) 138
humans (123) 123
index medicus (99) 99
female (84) 84
male (80) 80
middle aged (79) 79
aged (68) 68
lung neoplasms - drug therapy (64) 64
chemotherapy (60) 60
carcinoma, non-small-cell lung - drug therapy (58) 58
adult (55) 55
lung cancer (52) 52
lung neoplasms - pathology (47) 47
aged, 80 and over (40) 40
respiratory system (40) 40
cancer (37) 37
article (34) 34
treatment outcome (33) 33
carcinoma, non-small-cell lung - pathology (32) 32
lung cancer, non-small cell (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
neoplasm staging (30) 30
erlotinib (28) 28
care and treatment (27) 27
lung neoplasms - genetics (27) 27
antineoplastic agents - therapeutic use (26) 26
carcinoma, non-small-cell lung - genetics (24) 24
hematology, oncology and palliative medicine (24) 24
therapy (23) 23
open-label (22) 22
gefitinib (21) 21
lung neoplasms - mortality (21) 21
nsclc (21) 21
protein kinase inhibitors - therapeutic use (21) 21
docetaxel (20) 20
mutation (20) 20
clinical trials (19) 19
crizotinib (19) 19
research (19) 19
non-small cell lung cancer (18) 18
survival rate (18) 18
metastasis (17) 17
survival (17) 17
tumors (17) 17
lung neoplasms - therapy (16) 16
patients (16) 16
prognosis (16) 16
carcinoma (15) 15
carcinoma, non-small-cell lung - mortality (15) 15
receptor, epidermal growth factor - antagonists & inhibitors (15) 15
cell lung-cancer (14) 14
dose-response relationship, drug (14) 14
non-small cell lung carcinoma (14) 14
pulmonary/respiratory (14) 14
survival analysis (14) 14
acquired-resistance (13) 13
antineoplastic agents - adverse effects (13) 13
cancer therapies (13) 13
disease-free survival (13) 13
expression (13) 13
follow-up studies (13) 13
analysis (12) 12
antineoplastic agents (12) 12
retrospective studies (12) 12
safety (12) 12
abridged index medicus (11) 11
adenocarcinoma (11) 11
alectinib (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
breast-cancer (11) 11
carboplatin (11) 11
cisplatin (11) 11
drug therapy (11) 11
epidemiology (11) 11
maximum tolerated dose (11) 11
medicine & public health (11) 11
multicenter (11) 11
paclitaxel (11) 11
trial (11) 11
ceritinib (10) 10
combined modality therapy (10) 10
disease progression (10) 10
egfr (10) 10
immunotherapy (10) 10
lung neoplasms - metabolism (10) 10
non-small-cell lung cancer (10) 10
radiotherapy (10) 10
receptor, epidermal growth factor - genetics (10) 10
taxoids - administration & dosage (10) 10
tyrosine kinase inhibitor (10) 10
antimitotic agents (9) 9
cancer research (9) 9
carcinoma, non-small-cell lung - metabolism (9) 9
carcinoma, non-small-cell lung - therapy (9) 9
clinical trials as topic (9) 9
drug resistance, neoplasm - genetics (9) 9
growth-factor receptor (9) 9
incidence (9) 9
lymphomas (9) 9
mutations (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2016, 1st ed. 2016, Advances in experimental medicine and biology, ISBN 3319249320, Volume 890., x, 231
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics;... 
Lungs | Treatment | Cancer | Oncology | Cancer Research | Biomedicine
Book
2016, 1st ed. 2016, Advances in experiemntal medicine and biology, ISBN 3319242210, Volume 893, xiii, 228
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer-statistics and... 
Treatment | Lungs | Personalized medicine | Cancer | Oncology | Cancer Research | Internal Medicine | Molecular Medicine | Biomedicine
Book
2016, 1st ed. 2016., Advances in Experimental Medicine and Biology, ISBN 9783319242231, Volume 893
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and... 
Medicine | Cancer research | Internal medicine | Oncology | Molecular biology
Web Resource
2016, 1st ed. 2016., Advances in Experimental Medicine and Biology, ISBN 9783319249322, Volume 890
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics;... 
Medicine | Cancer research
Web Resource
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 897 - 907
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 02/2017, Volume 26, Issue 2 Supplement, pp. IA15 - IA15
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 06/2017, Volume 18, Issue 6, p. 1
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s11864-017-0479-8 
ALK | Brigatinib | Crizotinib | Alectinib | Lorlatinib | NSCLC | Sequence of therapy | Anaplastic lymphoma kinase | Ceritinib | Enzyme inhibitors | Development and progression | Lung cancer, Non-small cell | Drug therapy | Phosphotransferases | Health aspects | Testing
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue 18, pp. 3197 - 3200
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 11/2018, Volume 19, Issue 11, pp. 1 - 10
Journal Article
Future Oncology, ISSN 1479-6694, 08/2018, Volume 14, Issue 18, pp. 1875 - 1882
Anaplastic lymphoma kinase (ALK) gene rearrangements as driver genetic alterations occur in approximately 2-4% of non-small-cell lung cancer (NSCLC) patients.... 
NSCLC | anaplastic lymphoma kinase | alectinib | ACQUIRED-RESISTANCE | OPEN-LABEL | PF-2341066 | ANTITUMOR-ACTIVITY | REARRANGEMENTS | CHEMOTHERAPY | ONCOLOGY | CERITINIB | C-MET | CRIZOTINIB | INHIBITOR
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article